SOUTH EASTON, Mass. – Pressure BioSciences, Inc. (Nasdaq:PBIO) (“PBI” or the “Company”) today announced that Mr. Jeffrey N. Peterson, CEO of Target Discovery, Inc. (Palo Alto, CA), was elected to the Company’s Board of Directors effective Tuesday, June 21, 2011. The Company also announced that it has received gross proceeds of approximately $275,000 from the sale of additional securities in the second tranche of its $6.0 million Series C private placement. The Company has now received approximately $1.1 million in aggregate gross proceeds from the first two tranches of the Series C offering.

Mr. Peterson was elected contingent and effective upon the purchase of an aggregate of at least $500,000 of securities in the Series C private placement by Mr. Clayton A. Struve (Chicago, IL). Mr. Struve purchased $250,170 worth of securities on April 8, 2011 and an additional $250,450 worth of securities on June 21, 2011.

About Jeffrey N. Peterson

Mr. Peterson, currently the CEO of Target Discovery, Inc. (“TDI”), a biotechnology company, has broad executive, general management, multi-functional, multi-business, and international experience. He has guided TDI through 12 years of breakthrough proteomics platform tools development and positioning as an emerging leader in Personalized Medicine Diagnostics.

Prior to TDI, Mr. Peterson spent nine years in key management roles in Abbott Laboratories’ International and Diagnostics businesses. He last served as CEO and General Manager of Abbott South Africa. He played a management role in Abbott’s successful introduction and support of multiple new diagnostics instrument and reagent systems in Abbott’s X-System series, including the highly successful IMx. Mr. Peterson’s experience prior to Abbott included 11 years with General Electric’s Engineered Materials and Plastics businesses, spanning roles in strategic planning, business development, technology licensing, marketing/sales, operations/quality, and R&D.

Mr. Peterson holds BSChE and MSChE (Chemical Engineering) degrees from MIT. He serves on the Board and is Chairman Emeritus of the BayBio Institute, a non-profit organization serving the regional life science community, and on the Board of BayBio, the trade association for the life sciences industry in Northern California.